Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
G-CSF resistance of ELANE-mutant neutropenia depends on SERF1-containing truncated–neutrophil elastase aggregates
Ramesh C. Nayak, … , Carolyn M. Lutzko, Jose A. Cancelas
Ramesh C. Nayak, … , Carolyn M. Lutzko, Jose A. Cancelas
Published November 19, 2024
Citation Information: J Clin Invest. 2025;135(2):e177342. https://doi.org/10.1172/JCI177342.
View: Text | PDF
Research Article Hematology

G-CSF resistance of ELANE-mutant neutropenia depends on SERF1-containing truncated–neutrophil elastase aggregates

  • Text
  • PDF
Abstract

Severe congenital neutropenia (SCN) is frequently associated with dominant point mutations in ELANE, the gene encoding neutrophil elastase (NE). Chronic administration of granulocyte colony–stimulating factor (G-CSF) is a first-line treatment of ELANE-mutant (ELANEmut) SCN. However, some ELANEmut patients, including patients with ELANE start codon mutations, do not respond to G-CSF. Here, through directed granulopoiesis of gene-edited isogenic normal and patient-derived iPSCs, we demonstrate that ELANE start codon mutations suffice to induce G-CSF–resistant granulocytic precursor cell death and refractory SCN. ELANE start codon–mutated neutrophil precursors express predominantly nuclear N-terminally truncated alternate NE. Unlike G-CSF–sensitive ELANE mutations that induce endoplasmic reticulum and unfolded protein response stress, we found that the mutation of the ELANE translation initiation codon resulted in NE aggregates and activated proapoptotic aggrephagy, as determined by downregulated BAG1 expression, decreased BAG1/BAG3 ratio, NE colocalization with BAG3, and localized expression of autophagic LC3B. We found that SERF1, an RNA-chaperone protein, known to localize in misfolded protein aggregates in neurodegenerative diseases, was highly upregulated and interacted with cytoplasmic NE of mutant neutrophil precursors. Silencing of SERF1 enhanced survival and differentiation of iPSC-derived neutrophil precursors, restoring their responsiveness to G-CSF. These observations provide a mechanistic insight into G-CSF–resistant ELANEmut SCN, revealing targets for therapeutic intervention.

Authors

Ramesh C. Nayak, Sana Emberesh, Lisa R. Trump, Ashley M. Wellendorf, Abhishek K. Singh, Brice Korkmaz, Marshall S. Horwitz, Kasiani C. Myers, Theodosia A. Kalfa, Carolyn M. Lutzko, Jose A. Cancelas

×

Figure 1

Neutrophil precursors with mutation at the translation initiation codon (c.1A>G) of ELANE that is associated with cell death, differentiation arrest, and G-CSF resistance.

Options: View larger image (or click on image) Download as PowerPoint
Neutrophil precursors with mutation at the translation initiation codon ...
(A) PB ANCs and AMCs of a patient with ELANE translation initiation codon mutation (c.1A>G, NEp.M1V) from diagnosis at 3 months after birth up to 16 months. The patient was found to have leukopenia, severe neutropenia (ANC = 0), and monocytosis (AMC = 2720/mm3). G-CSF (20 μg/kg/day) administration showed minimal effect on ANCs. Donor granulocyte transfusion did not increase neutrophil counts. This patient underwent allogeneic bone marrow transplantation, resulting in ANC recovery. (B) Experimental schema of modeling of SCN with ELANE translation initiation codon mutation employing directed hematopoietic and granulopoietic differentiation of normal (healthy donor iPSCs), isogenic gene-edited GTG-KI (GTG knockin in place of ATG in one allele of ELANE gene of normal iPSCs), GTG-P1 (ELANE c.1A>G SCN patient–derived iPSCs), and GTG-C (correction of GTG to ATG in SCN patient GTG-P1 iPSCs). (C) Cell growth of normal, GTG-KI, GTG-P1, and GTG-C iPSC–derived hematopoietic progenitors (CD34+CD45+). (D) Quantification of the apoptosis of normal, GTG-KI, GTG-P1, and GTG-C neutrophil precursors (CD45+CD34–CD14–CD11b–CD15+/dim). (E) Flow cytometry analyses of the granulopoiesis (mature neutrophils: CD45+CD14–CD11b+CD16+CD66b+) of normal, GTG-KI, GTG-P1, and GTG-C iPSC–derived hematopoietic progenitors in the presence of 50 ng/mL G-CSF. (F) Quantification of the apoptosis of normal, GTG-KI, GTG-P1, and GTG-C neutrophil precursors (CD45+CD34–CD14–CD11b–CD15+) in the presence of 50 ng/mL and 1000 ng/mL G-CSF. (G and H) Quantification (G) and representative morphological microphotographs (H) of output cells of G-CSF–induced (50 ng/mL) differentiation of normal, GTG-KI, GTG-P1, and GTG-C iPSC–derived hematopoietic progenitors (Wright-Giemsa staining; original magnification, ×40). Data are presented as individual data and mean ± standard deviation of a minimum of 3 replicates per experiment and a minimum of 2 independent experiments. Differences between groups were evaluated using 1-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts